Cargando…

Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals

PURPOSE: Cancer incidence is rising in low- and middle-income countries, where resource constraints often complicate therapeutic decisions. Here, we perform a cost-effectiveness analysis to identify the optimal adjuvant chemotherapy strategy for patients with stage III colon cancer treated in South...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pumpalova, Yoanna, Rogers, Alexandra M., Tan, Sarah Xinhui, Herbst, Candice-lee, Ruff, Paul, Neugut, Alfred I., Hur, Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710350/ https://www.ncbi.nlm.nih.gov/pubmed/34936375 http://dx.doi.org/10.1200/GO.21.00279

Ejemplares similares

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
por: Tan, Sarah Xinhui, et al.
Publicado: (2023)

The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer
por: O’Neil, Daniel S, et al.
Publicado: (2023)

The Impact of Breast Cancer Treatment Delays on Survival Among South African Women
por: Pumpalova, Yoanna S, et al.
Publicado: (2022)

Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa
por: Mapanga, Witness, et al.
Publicado: (2022)

Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening in Patients Who Are Unscreened
por: Aziz, Zainab, et al.
Publicado: (2023)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Involvement in Chemotherapy Decision Making among Patients with Stage II and III Colon Cancer
por: Austin, Jessica D., et al.
Publicado: (2023)

Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy
por: O'Neil, Daniel S., et al.
Publicado: (2018)

Colorectal Cancer (CRC) treatment and associated costs in the public sector compared to the private sector in Johannesburg, South Africa
por: Herbst, Candice-lee, et al.
Publicado: (2020)

Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
por: Ingram, Myles A., et al.
Publicado: (2022)

Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV
por: Phakathi, Boitumelo, et al.
Publicado: (2021)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
por: Aspinall, Sherrie L, et al.
Publicado: (2015)

Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
por: Shibahara, Hidetoshi, et al.
Publicado: (2022)

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
por: Schippinger, W, et al.
Publicado: (2007)

Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer
por: Jeong, Woon Kyung, et al.
Publicado: (2015)

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?
por: Roda, Desamparados, et al.
Publicado: (2018)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients
por: Hsieh, Mei‐Chin, et al.
Publicado: (2016)

Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer
por: Dix-Peek, Thérèse, et al.
Publicado: (2023)

Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa
por: Ruff, Paul, et al.
Publicado: (2018)

South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment
por: Cubasch, Herbert, et al.
Publicado: (2016)

The Cryptosporidium parvum ApiAP2 gene family: insights into the evolution of apicomplexan AP2 regulatory systems
por: Oberstaller, Jenna, et al.
Publicado: (2014)

Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients
por: Morris, M, et al.
Publicado: (2007)

Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70
por: Lu, Chieh-Sheng, et al.
Publicado: (2015)

Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer
por: van Waalwijk, Maren A., et al.
Publicado: (2011)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
por: Yoshida, M., et al.
Publicado: (2014)

Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
por: Zhou, Meijiao, et al.
Publicado: (2022)

Cost-effectiveness of adjuvant chemotherapy with uracil–tegafur for curatively resected stage III rectal cancer
por: Hisashige, A, et al.
Publicado: (2008)

PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
por: Phakathi, Boitumelo, et al.
Publicado: (2023)

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
por: Gao, Peng, et al.
Publicado: (2018)

Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy
por: Malik, Yasir G., et al.
Publicado: (2020)

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review
por: To, Yat Hang, et al.
Publicado: (2023)

The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer
por: Collienne, Maike, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers
por: Soni, Amy, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b39dks6kf0auqe5f57v5o1cc29